References
- Swerdlow SH, Campo E, Harris NL, . WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
- Carbone A, Gloghini A. AIDS-related lymphomas: from pathogenesis to pathology. Br J Haematol 2005;130:662–670.
- Dunleavy K, Wilson WH. How I treat HIV-associated lymphoma. Blood 2012;119:3245–3255.
- Bayraktar UD, Ramos JC, Petrich A, . Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999–2008 and treated with curative intent in the AIDS Malignancy Consortium. Leuk Lymphoma 2012;53: 2383–2389.
- Coiffier B, Thieblemont C, Van Den Neste E, . Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 2010;116:2040–2045.
- Kaplan LD, Lee JY, Ambinder RF, . Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005;106:1538–1543.
- Sparano JA, Lee JY, Kaplan LD, . Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood 2010;115:3008–3016.
- Dunleavy K, Little RF, Pittaluga S, . The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood 2010;115:3017–3024.
- Lim ST, Karim R, Nathwani BN, . AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol 2005;23:4430–4438.
- Dunleavy K, Pittaluga S, Wayne A, . MYC + aggressive B-cell lymphomas: novel therapy of untreated Burkitt lymphoma (BL) and MYC + diffuse large B-cell lymphoma (DLBCL) with DA-EPOCH-R. Ann Oncol 2011;22(Suppl. 4): Abstract 071.
- Noy A, Kaplan L, Lee J. Feasibility and toxicity of a modified dose intensive R-CODOX-M/IVAC for HIV-associated Burkitt and atypical Burkitt lymphoma (BL): preliminary results of a prospective multicenter phase II trial of the AIDS Malignancy Consortium (AMC). Blood 2009;114(Suppl. 1):Abstract 3673.
- Lenz G, Wright G, Dave SS, . Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313–2323.
- Davis RE, Ngo VN, Lenz G, . Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010;463:88–92.
- Staudt L, Dunleavy K, Buggy J, . The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 modulates chronic active BCR signaling and induces tumor regression in relapsed/refractory ABC DLBCL. Blood 2011;118(Suppl. 1):Abstract 2716.